Search Results for “Sanofi” – media

Well-known products of foreign companies such as AZ, Eli Lilly, and Sanofi were disqualified

On November 14, the Shanxi Provincial Drug and Equipment Centralized Bidding and Procurement Center issued the “Notice on the Adjustment and Disposal of the Price of the Centralized Procurement of Amoxicillin and Other Drugs in the Guangdong Alliance” (hereinafter referred to as the “Notice”). It is worth noting that there are still 11 manufacturers and 20 specifications that refuse to reduce prices for rectification, including well-known pharmaceutical companies, including AstraZeneca, Sanofi, Eli Lilly and other foreign pharmaceutical companies, and their products include well-known brand drugs such as Plavix (clopidogrel bisulfate tablets), Iressa (gefitinib tablets), and Alimta (pemetrexed disodium for injection). The “Notice” emphasizes that the relevant drugs that refuse to accept the price rectification requirements will be disqualified from being selected and the selected price will be disqualified, and will be transferred to the alternative catalog. The platform will increase price risk warnings, and the task volume of the centralized ...
- Source: drugdu
- 31
- November 21, 2024
2.5 billion+2.3 billion! Sanofi adds more nuclear weapons

Original Xie Ling Arterial New Medicine October 18, 2024 08:27 Chongqing Yesterday (October 17th), Sanofi announced that it has reached an agreement with Orano Med, a subsidiary of the Orano Group, to further accelerate the development of next-generation radioligand therapy (RLT) by leveraging their expertise in combating rare cancers. According to the agreement, Sanofi and Oueno will jointly invest in a new entity operated under the Oueno Medical brand, focusing on the discovery, design, and clinical development of next-generation radioligand therapy (RLT) based on lead-212 (①¹² Pb) alpha emitting isotopes. Sanofi will make an equity investment of 300 million euros (approximately 2.313 billion yuan), accounting for approximately 16% of the equity of the new entity Orano Medical, with a valuation of 1.9 billion euros (approximately 14.648 billion yuan). At the beginning of last month, Sanofi announced a licensing agreement with RadioMedix and Orano Med for RLT, focusing on AlphaMedix, a ...
- Source: drugdu
- 83
- October 21, 2024
Sanofi invests $1.4bn in insulin production in Germany

Sanofi has announced a significant investment of €1.3bn ($1.4bn) to increase its insulin production capabilities with an expanded facility in Frankfurt, Germany. The facility will cover 36,000m² at Sanofi’s existing BioCampus site and become operational in 2029. Sanofi will execute the project with support from the German national government and the Hesse state government, subject to European Union approval. Sanofi manufacturing and supply global head Brendan O’Callaghan stated: “With this project, we reaffirm our commitment to help diabetes sufferers around the world. “We’re using the long-time expertise of our Frankfurt BioCampus and its highly qualified personnel.” The investment comes in the wake of the German government’s adoption of an official pharma strategy in 2023 to bolster support for pharmaceutical companies. The approach also aids in streamlining approval processes and enhances conditions for research and development within the country. Sanofi Germany chairman Heidrun Irschik-Hadjieff said: “Our planned investment underscores the central ...
- Source: drugdu
- 69
- August 5, 2024
Vir Bio trims staff and pipeline to focus on Sanofi-licensed programmes

Vir Biotechnology has signed a licensing agreement with Sanofi for three clinical-stage masked T-cell engagers (TCE) for cancer treatment. The US-based company has also started strategic restructuring, which includes a workforce reduction of approximately 25% and the discontinuation of its influenza and Covid-19 programmes. Vir will also phase out its T cell-based viral vector platform. The company expects to save approximately $50m each from staff cuts and pipeline reprioritisation, which will be reinvested into the Sanofi-licensed programmes. Vir reported $1.43bn in cash reserves at the end of Q2. The Sanofi-licensed TCE candidates include SAR446309, a dual inhibitor of HER2 and CD3; SAR446329, a dual-masked PSMA and CD3 TCE; and SAR446368, a dual-masked EGFR and CD3 TCE. The TCE candidates were developed using the protease-cleavable masking platform, which Sanofi acquired from Amunix Pharmaceuticals. Both SAR446309 and SAR446329 are being evaluated in Phase I trials in patients with metastatic treatment-resistant HER2-positive tumours ...
- Source: drugdu
- 69
- August 5, 2024
Sanofi & Regeneron Drug Dupixent Gets EMA Approval as the First Biologic COPD Med

European Medicines Agency approval of Dupixent in chronic obstructive pulmonary disease makes the drug the first biologic therapy approved for treating the prevalent respiratory condition. In COPD, Dupixent addresses what’s called type 2 inflammation. By Frank Vinluan Inflammation that develops in chronic obstructive pulmonary disorder stems from different causes. A new regulatory decision in Europe makes Sanofi and Regeneron Pharmaceuticals drug Dupixent the first biologic therapy approved for COPD driven by one particular type of inflammation. The European Medicines Agency (EMA) has approved Dupixent for adults with uncontrolled COPD that is also characterized by raised blood levels of eosinophils, a type of white blood cell. COPD patients typically take multiple medications to manage the chronic condition. The new Dupixent approval, announced just prior to the Independence Day holiday in the U.S., covers use of the injectable drug as an add-on maintenance treatment for patients whose COPD is uncontrolled by available therapies. ...
- Source: drugdu
- 87
- July 9, 2024
EMA approval of Sanofi/Regeneron’s Dupixent fills biologic gap in COPD

Following the European Medicines Agency (EMA) approval of Sanofi/Regeneron’s Dupixent (Dupilumab) on July, 03 2024, Asiyah Nawab, Pharma Analyst at GlobalData, offers her view: “Dupixent, a monoclonal antibody (mAb) targeting interleukin-4 (IL4) and interleukin-13 (IL13) pathways, has been approved by the EMA as the first biologic for uncontrolled chronic obstructive pulmonary disease (COPD) patients. It is to be used specifically as an add-on maintenance treatment, given alongside the standard of care (SoC), with a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA. The approval is set to improve the treatment landscape for COPD and offer patients a treatment option with potential to improve quality of life,” states Nawab “After reviewing the data published from Sanofi/Regeneron’s two landmark phase 3 studies (BOREAS and NOTUS), Dupixent (dupilumab) was able to significantly reduce moderate or ...
- Source: drugdu
- 107
- July 6, 2024
Chen Jining, Secretary of Shanghai Municipal Party Committee, met with Paul Han, CEO of French Sanofi Group

Chen Jining, Secretary of the Municipal Party Committee of Shanghai Municipality, met with Paul Han, CEO of Sanofi Group of France, and his delegation on the morning of June 26th. Chen Jining said that biomedicine is one of the three leading industries that Shanghai focuses on. We actively play the role of reform and opening up the test bed, around basic research, clinical trials, approval and supervision, health insurance, introduced a series of early and pilot implementation of policies and initiatives, to more competitive innovation advantages, industrial advantages, market advantages and comprehensive cost advantages, the whole chain to promote biomedical science and technology innovation and industrial development, and effectively promote people’s health and well-being. Sanofi is a leading global pharmaceutical and healthcare enterprise, welcome to grasp the opportunity of Shanghai’s industrial transformation, further increase the investment layout in Shanghai, and put more innovative R&D and manufacturing in Shanghai. We will ...
- Source: drugdu
- 101
- June 28, 2024
FDA Approves Regeneron and Sanofi’s Kevzara to Treat Patients with Active Polyarticular Juvenile Idiopathic Arthritis

Don Tracy, Associate Editor Approval for Kevzara was based on controlled studies, pharmacokinetic data from adults with rheumatoid arthritis, and pediatric-specific studies on pharmacokinetics. The FDA has approved Regeneron’s and Sanofi’s approved Kevzara (sarilumab) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients weighing over 138 lbs. According to a joint press release, the approval was based on results of controlled studies and pharmacokinetic data from adults with rheumatoid arthritis (RA), as well as pediatric-specific studies on pharmacokinetics, pharmacodynamics, dosing, and safety.1 “Polyarticular juvenile idiopathic arthritis can be a painful disease for children where multiple joints are impacted by this chronic inflammation,” said George D. Yancopoulos, MD, PhD, board co-chair, president, chief scientific officer, Regeneron, in a press release. “Not only are their daily lives impacted, but their futures can be disrupted without adequate treatment. The approval of Kevzara in polyarticular juvenile idiopathic arthritis provides these vulnerable ...
- Source: drugdu
- 136
- June 13, 2024
Sanofi’s Sarclisa shows significant promise in treating myeloma

Sanofi’s Sarclisa, a novel treatment for multiple myeloma, has demonstrated a substantial improvement in progression-free survival for patients ineligible for transplant. The phase 3 IMROZ study revealed that Sarclisa (also known as isatuximab), combined with a VRd regimen, reduced the risk of disease progression or death by 40% compared to VRd alone. The study, which was presented at the American Society of Clinical Oncology (ASCO) annual meeting, marks a significant advancement in the treatment of newly diagnosed multiple myeloma (NDMM). The full data, published in the New England Journal of Medicine, will inform future regulatory submissions. Professor Graham Jackson, a haematologist and advisor for Myeloma UK, highlighted the importance of the findings: “Effective first-line treatment is essential in managing and delaying disease progression for newly diagnosed multiple myeloma patients. He added: “The significant progression-free survival demonstrated in the IMROZ study reinforces the potential of isatuximab-VRd to improve outcomes for newly ...
- Source: drugdu
- 78
- June 7, 2024
Sanofi signs $1.2bn licensing agreement for Novavax’s Covid-19 vaccine

Sanofi has signed a $1.2bn licensing agreement with Novavax to co-commercialise its stand-alone adjuvanted Covid-19 vaccine. Starting in 2025, the drugmaker will co-commercialise the vaccine worldwide, except for in countries such as India, South Korea, and Japan where Novavax already has existing partnerships in place. As per the “co-exclusive” agreement, Sanofi will also support certain R&D, regulatory, and commercial expenses. The American vaccine company has faced tough times in the post-Covid-19 landscape, going as far as to issue a “going concern” warning in 2023 about its ability to continue operating. At the time, Novavax said it was subject to “significant uncertainty” concerning future sales and funding from the US Government. Following the deal with Sanofi, the removal of this warning was noted in Novavax’s first quarter 2024 financial results and operational highlights released today. Novavax CEO John Jacobs told CNBC that the agreement with Sanofi would allow it to lift ...
- Source: drugdu
- 71
- May 14, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.